Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | ME2 | P23368 | 1/20 | 0.64 |
| ▸ | ME1 | P48163 | 1/20 | 0.64 |
| ▸ | ME3 | Q16798 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | GFER | P55789 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292827 | 0.88 | KMT2A (0.66) | KMT2AME2ME1ME3MEN1 | |
| SCHEMBL2292606 | 0.88 | KMT2A (0.66) | KMT2AMEN1MAPTGFERL3MBTL1 | |
| SCHEMBL2290466 | 0.85 | KMT2A (0.88) | KMT2AMEN1MAPTGFERL3MBTL1 | |
| SCHEMBL3799031 | 0.84 | ME2 (0.64) | KMT2AME2ME1ME3MEN1 | |
| SCHEMBL2824010 | 0.84 | MEN1 (0.72) | KMT2AME2ME1ME3MEN1 | |
| SCHEMBL3794409 | 0.81 | ME2 (0.68) | KMT2AME2ME1ME3MEN1 | |
| Hydrochloric Acid SCHEMBL27433739 | 0.81 | KMT2A (0.65) | KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27435595 | 0.81 | SIGMAR1 (0.67) | — | |
| SCHEMBL2821852 | 0.80 | GFER (0.53) | KMT2AMEN1MAPTGFERL3MBTL1 | |
| SCHEMBL4375437 | 0.79 | KMT2A (0.72) | KMT2AMEN1GFERALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| EP-2155736-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK Holdings Co., Ltd. (KR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140198-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO., LTD. (KR) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, OPRD1, OPRL1 | KMT2A 1354/4885ME2 3685/4885ME1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.